

# Novaestiq's Partner Croma-Pharma Announces Submission to the U.S. Food and Drug Administration for saypha® MagIQ™

*1st submission in the United States for saypha® line of dermal fillers represents a key Novaestiq milestone*

SOUTHLAKE, TX, UNITED STATES, August 21, 2024 /EINPresswire.com/ -- Novaestiq Corp., a growth-oriented aesthetic company that focuses on delivering intelligent and innovative



Novaestiq Company Logo

skin solutions to practices and patients announced today that earlier this year its partner Croma-Pharma GmbH finalized submission of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the saypha® MagIQ™ hyaluronic acid dermal filler. Novaestiq plans to commercialize saypha® MagIQ™ beginning in early 2025.



The submission is a foundational milestone for Novaestiq and supports our effort to create the next great aesthetic company"

*Miles Harrison, CEO*

"We are delighted that our partner Croma has submitted this first filler product to the FDA," said Miles Harrison, Chief Executive Officer, Novaestiq. "The submission is a foundational milestone for Novaestiq and supports our effort to create the next great aesthetic company. We look forward to continued collaboration with our partners at Croma as we drive our "[Aesthetics for All™](#)" ethos."

The PMA application includes results from the U.S. pivotal study, which evaluated the safety and effectiveness of the products in a multicenter, blinded, split face, controlled, non-inferiority designed trial. Patients were followed for 12 months from initial treatment. A total of 270 patients were enrolled and received saypha® MagIQ™ in one NLF and Juvederm® Ultra XC in the contralateral NLF. saypha® MagIQ™ met the primary endpoint at 24 weeks. Additional information will be shared at upcoming medical conferences.

saypha® MagIQ™ has 8+ years of global experience and is manufactured by Croma in Leobendorf, Austria. More than 22 million syringes have been manufactured from the saypha® product line demonstrating high quality, a proven safety profile, and consistent performance in

over 80 markets around the world. Novaestiq anticipates that their partner Croma will be submitting a second filler product for approval early in 2025.

## About Novaestiq

Novaestiq is a private, growth-oriented company that boasts a broad range of aesthetic and dermatology products that are both practice and patient/consumer focused. Novaestiq is poised to bring a variety of intelligent and innovative skin solutions to the market in the coming months and years. With a strong emphasis on driving practice success, Novaestiq is set to redefine industry standards. [www.novaestiq.com](http://www.novaestiq.com)

For media inquiries or further information, please contact:

Drew Fine, Chief Commercial Officer. Email: [drew@novaestiq.com](mailto:drew@novaestiq.com)

Media Relations Novaestiq Corp. Email: [inquiries@novaestiq.com](mailto:inquiries@novaestiq.com)

Drew Fine

Novaestiq

[email us here](#)

Visit us on social media:

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/736932933>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.